Manuel A F V Gonalves

List of Publications by Year in Descending Order

53 papers	1,965 citations	24 h-index	44 g-index
55 ext. papers	2,226 ext. citations	8.9 avg, IF	5.18 L-index

#	Paper	IF	Citations
53	A primer to gene therapy: Progress, prospects, and problems. *Journal of Inherited Metabolic Disease*, **2021**, 44, 54-71	5.4	4
52	Broadening the reach and investigating the potential of prime editors through fully viral gene-deleted adenoviral vector delivery. *Nucleic Acids Research*, **2021**, 49, 11986-12001	20.1	3
51	Precise and broad scope genome editing based on high-specificity Cas9 nickases. *Nucleic Acids Research*, **2021**, 49, 1173-1198	20.1	8
50	TGF-β-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 616610	5.7	7
49	Adenoviral Vectors Meet Gene Editing: A Rising Partnership for the Genomic Engineering of Human Stem Cells and Their Progeny. *Cells*, **2020**, 9,	7.9	8
48	Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components. *Gene Therapy*, **2020**, 27, 209-225	4	18
47	Expanding the editable genome and CRISPR-Cas9 versatility using DNA cutting-free gene targeting based on in trans paired nicking. *Nucleic Acids Research*, **2020**, 48, 974-995	20.1	12
46	Novel Therapeutic Approaches for the Treatment of Retinal Degenerative Diseases: Focus on CRISPR/Cas-Based Gene Editing. *Frontiers in Neuroscience*, **2020**, 14, 838	5.1	8
45	High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of Gene Repair Tools and Strategies in Human Cells. *Cells*, **2020**, 9,	7.9	11
44	Genomic Engineering in Human Hematopoietic Stem Cells: Hype or Hope?. *Frontiers in Genome Editing*, **2020**, 2, 615619	2.5	2
43	A Small Key for a Heavy Door: Genetic Therapies for the Treatment of Hemoglobinopathies. *Frontiers in Genome Editing*, **2020**, 2, 617780	2.5	1
42	The Chromatin Structure of CRISPR-Cas9 Target DNA Controls the Balance between Mutagenic and Homology-Directed Gene-Editing Events. *Molecular Therapy - Nucleic Acids*, **2019**, 16, 141-154	10.7	25
41	Intronic variants in FSHD: testing the potential for CRISPR-Cas9 genome editing. *Journal of Medical Genetics*, **2019**, 56, 828-837	5.8	15
40	DNA, RNA, and Protein Tools for Editing the Genetic Information in Human Cells. *IScience*, **2018**, 6, 247-263	6.1	19
39	Correction of Recessive Dystrophic Epidermolysis Bullosa by Transposon-Mediated Integration of COL7A1 in Transplantable Patient-Derived Primary Keratinocytes. *Journal of Investigative Dermatology*, **2017**, 137, 836-844	4.3	19
38	The Chromatin Structure Differentially Impacts High-Specificity CRISPR-Cas9 Nuclease Strategies. *Molecular Therapy - Nucleic Acids*, **2017**, 8, 558-563	10.7	24
37	In trans paired nicking triggers seamless genome editing without double-stranded DNA cutting. *Nature Communications*, **2017**, 8, 657	17.4	51

36	Engineered Viruses as Genome Editing Devices. *Molecular Therapy*, **2016**, 24, 447-57	11.7	95
35	Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells. *Scientific Reports*, **2016**, 6, 37051	4.9	46
34	Probing the impact of chromatin conformation on genome editing tools. *Nucleic Acids Research*, **2016**, 44, 6482-92	20.1	79
33	Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations. *Nucleic Acids Research*, **2016**, 44, 1449-70	20.1	53
32	The emerging role of viral vectors as vehicles for DMD gene editing. *Genome Medicine*, **2016**, 8, 59	14.4	12
31	Genome editing at the crossroads of delivery, specificity, and fidelity. *Trends in Biotechnology*, **2015**, 33, 280-91	15.1	107
30	Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells. *Scientific Reports*, **2014**, 4, 5105	4.9	99
29	Adenoviral vector DNA for accurate genome editing with engineered nucleases. *Nature Methods*, **2014**, 11, 1051-7	21.6	108
28	Construction and characterization of adenoviral vectors for the delivery of TALENs into human cells. *Methods*, **2014**, 69, 179-87	4.6	29
27	Lentiviral vectors encoding zinc-finger nucleases specific for the model target locus HPRT1. *Methods in Molecular Biology*, **2014**, 1114, 181-99	1.4	7
26	Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. *Human Gene Therapy*, **2013**, 24, 78-96	4.8	45
25	Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells. *Journal of Gene Medicine*, **2013**, 15, 1-11	3.5	20
24	Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases. *Human Gene Therapy Methods*, **2013**, 24, 399-411	4.9	16
23	Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. *Molecular Therapy*, **2013**, 21, 1695-704	11.7	52
22	Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells. *Nucleic Acids Research*, **2013**, 41, e63	20.1	216
21	Concerted nicking of donor and chromosomal acceptor DNA promotes homology-directed gene targeting in human cells. *Nucleic Acids Research*, **2012**, 40, 3443-55	20.1	11
20	Nonspaced inverted DNA repeats are preferential targets for homology-directed gene repair in mammalian cells. *Nucleic Acids Research*, **2012**, 40, 1984-99	20.1	11
19	Myogenic properties of human mesenchymal stem cells derived from three different sources. *Cell Transplantation*, **2012**, 21, 153-73	4	65

18	Adenoviral vectors stimulate glucagon transcription in human mesenchymal stem cells expressing pancreatic transcription factors. *PLoS ONE*, **2012**, 7, e48093	3.7	9
17	Long-term contribution of human bone marrow mesenchymal stromal cells to skeletal muscle regeneration in mice. *Cell Transplantation*, **2011**, 20, 217-31	4	47
16	Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes. *Molecular Therapy*, **2011**, 19, 1331-41	11.7	21
15	Rapid and sensitive lentivirus vector-based conditional gene expression assay to monitor and quantify cell fusion activity. *PLoS ONE*, **2010**, 5, e10954	3.7	9
14	Stimulation of homology-directed gene targeting at an endogenous human locus by a nicking endonuclease. *Nucleic Acids Research*, **2009**, 37, 5725-36	20.1	30
13	Genetic complementation of human muscle cells via directed stem cell fusion. *Molecular Therapy*, **2008**, 16, 741-8	11.7	29
12	Targeted chromosomal insertion of large DNA into the human genome by a fiber-modified high-capacity adenovirus-based vector system. *PLoS ONE*, **2008**, 3, e3084	3.7	18
11	Human mesenchymal stem cells ectopically expressing full-length dystrophin can complement Duchenne muscular dystrophy myotubes by cell fusion. *Human Molecular Genetics*, **2006**, 15, 213-21	5.6	68
10	Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells. *Molecular Therapy*, **2006**, 13, 976-86	11.7	30
9	Modular and excisable molecular switch for the induction of gene expression by the yeast FLP recombinase. *BioTechniques*, **2006**, 41, 711-3	2.5	5
8	Adenovirus: from foe to friend. *Reviews in Medical Virology*, **2006**, 16, 167-86	11.7	85
7	Adeno-associated virus: from defective virus to effective vector. *Virology Journal*, **2005**, 2, 43	6.1	129
6	Endowing human adenovirus serotype 5 vectors with fiber domains of species B greatly enhances gene transfer into human mesenchymal stem cells. *Stem Cells*, **2005**, 23, 1598-607	5.8	51
5	A concise peer into the background, initial thoughts and practices of human gene therapy. *BioEssays*, **2005**, 27, 506-17	4.1	16
4	Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability. *Journal of Virology*, **2005**, 79, 3146-62	6.6	40
3	Stable transduction of large DNA by high-capacity adeno-associated virus/adenovirus hybrid vectors. *Virology*, **2004**, 321, 287-96	3.6	19
2	Efficient generation and amplification of high-capacity adeno-associated virus/adenovirus hybrid vectors. *Journal of Virology*, **2002**, 76, 10734-44	6.6	21
1	Generation of a high-capacity hybrid vector: packaging of recombinant adenoassociated virus replicative intermediates in adenovirus capsids overcomes the limited cloning capacity of adenoassociated virus vectors. *Virology*, **2001**, 288, 236-46	3.6	32